Anthropic acquires stealth AI startup Coefficient Bio in $400M deal: reports
fiercehealthcare - AI powerhouse Anthropic is continuing its push into the healthcare arena with the acquisition of previously stealth AI startup Coefficient Bio in a $400 million stock deal, according to reporting from The Information and Eric Newcomer.
AI Summary: Anthropic has acquired stealth biotech Coefficient Bio in a reported $400 million deal, signaling a major push by an AI developer into drug discovery. The acquisition folds computational prowess into wet‑lab capabilities, reshaping who might lead future therapeutic discovery and prompting competitors to wonder if they missed the memo.
Common metabolic enzyme could predict cancer immunotherapy benefits—and help more patients respond
medicalxpress - Immunotherapies have transformed cancer treatment by helping the immune system recognize and attack tumors. They work for only about 20% of patients, though, and doctors still struggle to predict who will benefit.
AI Summary: New research identifies a common metabolic enzyme as a potential biomarker predicting benefit from cancer immunotherapy, and investigators propose that controlling intracellular metabolite routing could enhance responses. Together, these findings suggest metabolic pathways are both useful predictors and actionable targets to convert non‑responders into responders.
- Metabolic signals predict and boost immunotherapy responses (5)
- Other related research and expert commentary (8)
- Scaling CAR‑T: access, effects, and biomarker collaborations (3)
- Unmasking tumors: epigenetic and immune reprogramming strategies (4)
- All Other Stories
Metabolic signals predict and boost immunotherapy responses
Other related research and expert commentary
Scaling CAR‑T: access, effects, and biomarker collaborations
Unmasking tumors: epigenetic and immune reprogramming strategies
All Other Stories
Rabi Hanna: First-in-Human CRISPR/Cas12a Therapy in Sickle Cell Disease
oncodaily - Rabi Hanna, Pediatric Blood and Marrow Transplant Program Director, and Chairman at the Department of Pediatric Hematology-Oncology and BMT at Cleveland Clinic, shared a post on LinkedIn: “I am excited […]
AI Summary: A first‑in‑human CRISPR/Cas12a therapy for sickle cell disease has treated initial patients, building on preclinical gene‑editing successes that reversed severe disease in models. The advance underscores rapid translation from lab to clinic and renews hope for durable cures—while reminding everyone that the safety and long‑term durability questions remain firmly on the table.
Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline
esmo - This ESMO–EURACAN CPG provides key recommendations for the diagnosis, staging, treatment and follow-up for uveal melanoma. It includes percutaneous hepatic perfusion and tebentafusp as treatment options for metastatic disease, reflecting emerging evidence…
AI Summary: ESMO–EURACAN released a comprehensive clinical practice guideline for uveal melanoma covering diagnosis, staging, surveillance and systemic management. The guidance clarifies best practices for multidisciplinary care, risk stratification and therapeutic sequencing, aiming to standardize treatment and follow‑up for a rare but high‑risk ocular tumour.
FDA identifies eight deaths tied to Amgen's Tavneos
Max Bayer / endpoints - The FDA on Tuesday flagged more than 70 cases of severe liver injury and eight deaths associated with Amgen’s autoimmune treatment Tavneos, but the company said it previously notified the agency about the risk of ...
AI Summary: The FDA has tied eight patient deaths to Amgen’s drug Tavneos, prompting heightened regulatory review and industry concern. Reports outline safety signals and agency actions as clinicians and manufacturers reassess risk‑benefit profiles, while regulators weigh labeling, monitoring or other interventions to protect patients.
Biogen to acquire Apellis for $5.6B
Elizabeth Cairns / endpoints - Biogen has made a $5.6 billion deal to acquire Apellis Pharmaceuticals, the companies announced Tuesday. The deal will allow Biogen to get hold of the kidney disease drug Empaveli and the eye disease therapy Syfovre ...
AI Summary: Biogen agreed to acquire Apellis Pharmaceuticals for $5.6 billion, a deal pitched as a strategic move to broaden Biogen’s pipeline and bolster its biopharma foothold. Analysts and company spokespeople framed the purchase as value‑accretive, even as skeptics question integration risks and the price tag in a cautious market.
Phase 3 ATOMIC trial Updates: Atezolizumab plus FOLFOX for Stage III dMMR Colon Cancer
oncodaily - Patients with stage III colon cancer are typically treated with surgical resection followed by adjuvant chemotherapy with a fluoropyrimidine-plus-oxaliplatin regimen. However, approximately 30% of patients with stage III disease experience […]
AI Summary: Phase 3 ATOMIC updates show that adding atezolizumab to FOLFOX/mFOLFOX6 improves disease‑free survival in patients with Stage III dMMR colon cancer, with a substantial reduction in recurrence risk reported. The results suggest immunotherapy may become integral to adjuvant treatment for this biomarker‑defined subgroup.
- ATOMIC breakthrough: atezolizumab reduces recurrence in dMMR colon patients (3)
- From the wards: MSI-H immunotherapy expands beyond colon (3)
- On the frontline: colorectal biomarkers and therapy innovations (6)
- Other headlines: cancer research news outside ATOMIC focus (1)
- All Other Stories
ATOMIC breakthrough: atezolizumab reduces recurrence in dMMR colon patients
From the wards: MSI-H immunotherapy expands beyond colon
On the frontline: colorectal biomarkers and therapy innovations
Other headlines: cancer research news outside ATOMIC focus
All Other Stories
E.P.A. Targets Microplastics and Drugs in Drinking Water
Hiroko Tabuchi and Maxine Joselow / nytimes - The move drew praise from leaders of the Make America Healthy Again movement who had recently criticized the agency’s handling of toxic chemicals.
AI Summary: Federal agencies are moving from polite warnings to action on contaminants people actually drink. The EPA is targeting microplastics and trace pharmaceuticals in drinking water, while ARPA‑H is pouring funding into health-impact studies, and other agencies are considering formal contaminant designations to force testing, cleanup and new standards. Small particles, big headache.
Eli Lilly’s Neuro Prospects Expand to Sleep Science With $6.3B Centessa Acquisition
Frank Vinluan / medcitynews - Centessa Pharmaceuticals’ cleminorexton is part of the orexin agonist drug class, which could introduce a new approach to the treatment of narcolepsy and other sleep disorders. Acquiring Centessa brings Eli Lilly into a group of clinical-stage orexin agon…
AI Summary: Eli Lilly announced a $6.3 billion acquisition of Centessa to secure a promising narcolepsy/sleep-disorder candidate and expand its neuroscience portfolio. The deal fast-tracks Lilly into sleep science, buying late-stage assets rather than relying on in-house miracles — a tidy shortcut to diversifying its neurotherapeutics pipeline.
Eli Lilly Bets €2.4B on AI-Designed Drugs in New Insilico Medicine Deal
oncodaily - In a sweeping push to expand its pipeline and embrace artificial intelligence in drug discovery, Eli Lilly and Company has announced two major strategic moves: a multi-billion-dollar collaboration with Insilico […]
AI Summary: Eli Lilly struck a major partnership with Insilico Medicine to accelerate AI‑designed drug programs, providing a substantial upfront payment and committing to multiyear development milestones and potential payouts worth roughly in the billions. The deal expands Lilly’s AI drug discovery footprint and signals big pharma’s growing bet on algorithmic chemistry.
Kailera Plans IPO for Obesity Drug That Could Top Lilly’s Zepbound
Frank Vinluan / medcitynews - Kailera Therapeutics’ planned IPO will fund ongoing clinical development of a pipeline led by a drug that could rival Eli Lilly’s Zepbound in both efficacy and tolerability. Meanwhile, Renaissance Capital’s recap of first quarter 2026 IPOs shows slowing a…
AI Summary: Kailera announced plans for an initial public offering to fund late‑stage development of a Phase 3 obesity candidate licensed from Hengrui, positioning the program as a potential rival to Lilly’s Zepbound. The IPO aims to accelerate clinical work and commercial readiness as investors weigh market appetite for next‑generation weight‑loss therapies.
- Antimicrobial resistance risk found in South African wastewater (1)
- Financing rush: IPOs and venture cash fueling obesity drug race (4)
- New commercial models: subscriptions, telehealth, expanded patient access (4)
- Regulatory wins and science shaping next-generation weight-loss drugs (6)
- All Other Stories
Antimicrobial resistance risk found in South African wastewater
Financing rush: IPOs and venture cash fueling obesity drug race
New commercial models: subscriptions, telehealth, expanded patient access
Regulatory wins and science shaping next-generation weight-loss drugs
All Other Stories
Teens are driving the demand for online abortion pills via telehealth
medicalxpress - Teens in the U.S. are obtaining medication abortion pills through telehealth, and young people aged 18 to 24 are ordering medication abortion at much higher rates than older adults.
AI Summary: Telehealth provision of medication abortion has surged, reducing travel for many and prompting a noticeable uptick in online requests from teenagers. Reports show virtual care is reshaping access patterns and forcing healthcare systems and regulators to confront new realities around remote prescribing, confidentiality, and youth access to reproductive services.
Spatial mapping technique allows researchers to understand tumor architecture
medicalxpress - Tumors contain many different types of cells organized in complex spatial patterns that can influence how the disease progresses. Because of this, it is hard to predict how a tumor will develop and respond to treatment. Researchers at the University of Il…
AI Summary: Advanced spatial mapping techniques revealed how tumor architecture and local microenvironments reorganize — including changes driven by tumor‑linked viruses — altering immune cell positioning and signaling. The work provides a high‑resolution blueprint for understanding treatment resistance and suggests new targets for precision therapies that consider the tumor’s geographic biology, not just its genetics.
- Field report: Immune geography dictates therapy response and resistance (4)
- On scene: microbes and viruses remap tumor microenvironments (3)
- On the ground: spatial multi-omics maps tumor architecture (4)
- Other: Miscellaneous tumor biology, therapies, biomarkers (18)
- All Other Stories
Field report: Immune geography dictates therapy response and resistance
On scene: microbes and viruses remap tumor microenvironments
On the ground: spatial multi-omics maps tumor architecture
Other: Miscellaneous tumor biology, therapies, biomarkers
All Other Stories
AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trial
Lei Lei Wu / endpoints - New clinical trial data on the in vivo CAR-T therapy that AstraZeneca acquired last year suggest that while the experimental treatment can curb multiple myeloma in some patients, it may not be safer than the ...
AI Summary: Early reports from a phase 1 in‑vivo CAR‑T program show promising anti‑myeloma activity following direct in‑body CAR induction targeting BCMA, but investigators also reported a treatment‑related death in a China trial. The mixed signals underscore the potential of in‑vivo CAR approaches while spotlighting safety, dosing and monitoring challenges that must be resolved before wider adoption.
- AstraZeneca's in‑vivo CAR‑T: early wins, serious safety questions (4)
- Myeloma community reacts: experts, conferences and paper highlights (7)
- Next‑gen T‑cell strategies and regulatory hurdles (4)
- All Other Stories
AstraZeneca's in‑vivo CAR‑T: early wins, serious safety questions
Myeloma community reacts: experts, conferences and paper highlights
Next‑gen T‑cell strategies and regulatory hurdles
All Other Stories
EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib
esmo - It is intended for the treatment of paediatric patients with low-grade glioma with BRAF alterations whose disease has progressed after one or more prior systemic therapies
AI Summary: Five‑year results from KEYNOTE‑671 indicate perioperative pembrolizumab yields sustained clinical benefit in early‑stage non‑small‑cell lung cancer, improving outcomes even when pathological complete response is not achieved. The data bolster the case for integrating immune checkpoint blockade into surgical-era treatment strategies, shifting conversations about neoadjuvant and adjuvant sequencing.
- Frontline precision: KRAS G12D and EGFR targeted advances in NSCLC (4)
- Insider view: evolving IO biology, toxicity and access debates (3)
- On-the-ground: Neoadjuvant immunotherapy and radiotherapy reshaping lung surgery (4)
- OTHER: assorted oncology updates outside perioperative NSCLC focus (4)
- All Other Stories
Frontline precision: KRAS G12D and EGFR targeted advances in NSCLC
Insider view: evolving IO biology, toxicity and access debates
On-the-ground: Neoadjuvant immunotherapy and radiotherapy reshaping lung surgery
OTHER: assorted oncology updates outside perioperative NSCLC focus
All Other Stories
“Me engañaron”: agentes encadenan a un padre que había ido al ICE a reunirse con sus hijos
Claudia Boyd-Barrett and Renuka Rayasam and Amanda Seitz / kffhealthnews - Se supone que la agencia que cuida a niños que llegan solos al país deben reunirlos pronto con sus familias o cuidadores. Pero cada vez más los usan como “carnada” para arrestar a los padres.
AI Summary: Gilead struck a deal to acquire Ouro Medicines for roughly $1.68–1.7 billion, securing an immune‑modulating autoimmune program intended to reset pathological immune responses. The transaction combines upfront cash and potential milestones, expanding Gilead’s pipeline and signaling continued industry appetite for bolt‑on buys to chase novel therapeutics.
Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia
esmo - Findings from the RECITE study
AI Summary: A clinical study found romiplostim effective in treating and preventing recurrent persistent chemotherapy‑induced thrombocytopenia, restoring platelet counts and enabling continuation of scheduled cytotoxic therapy. Patients experienced fewer delays and dose reductions, positioning romiplostim as a useful strategy to keep chemo on track—because, apparently, platelet math still runs cancer care.
Results from the Phase 2 POLAR Trial: Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer
oncodaily - Pancreatic cancer remains one of the most challenging malignancies to treat, particularly in the metastatic setting, where immunotherapy has historically shown minimal activity. However, a biologically defined subset of patients […]
AI Summary: The Phase 2 POLAR trial presented results evaluating pembrolizumab combined with olaparib in homologous recombination–deficient metastatic pancreatic cancer, including safety, response rates and biomarker analyses. Investigators observed signals of activity in HRD‑selected patients, suggesting the immunotherapy–PARP inhibitor combination merits larger randomized testing rather than immediate headline glory.
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong
abcnews - Federal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong about one of his company's cancer drugs
AI Summary: The FDA issued warnings over promotional materials and public statements related to a cancer drug associated with a biotech entrepreneur, finding claims that could mislead patients and investors. The agency asked the company to correct materials and refrain from unsubstantiated efficacy or safety assertions while oversight and compliance reviews continue.
FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs
Frank Vinluan / medcitynews - Denali Therapeutics’ Avlayah received FDA approval for treating Hunter syndrome, a rare neurological disorder. The biologic medicine uses Denali’s proprietary drug delivery technology to cross the protective blood-brain barrier. The post FDA Approval for …
AI Summary: Regulators granted Denali accelerated approval for a brain‑penetrant therapy, recognizing promising early efficacy in a rare neurological indication and addressing unmet needs in CNS drug delivery. The pathway requires confirmatory trials to verify clinical benefit while enabling earlier patient access to a novel mechanism targeting central nervous system disease.